When to Start Medications for Elevated BUA (Blood Uric Acid) in Asymptomatic Patients
For asymptomatic hyperuricemia (serum uric acid >6.8 mg/dL with no prior gout flares or tophi), do NOT start urate-lowering therapy (ULT). 1
General Recommendation for Asymptomatic Hyperuricemia
The 2020 American College of Rheumatology guidelines conditionally recommend against initiating ULT in patients with asymptomatic hyperuricemia (serum uric acid >6.8 mg/dL) who have never experienced gout flares or developed subcutaneous tophi. 1 This recommendation is based on the poor number needed to treat—24 patients would need treatment for 3 years to prevent a single incident gout flare, making routine treatment unjustified from a risk-benefit perspective. 1
Critical Exceptions: When to START Medication Despite Being Asymptomatic
You should initiate ULT in asymptomatic hyperuricemia patients if they have ANY of the following high-risk features:
After First Gout Flare (No Longer Truly Asymptomatic)
- CKD stage ≥3 (eGFR <60 mL/min/1.73 m²): Conditionally recommend starting ULT 1
- Serum uric acid >9 mg/dL: Conditionally recommend starting ULT 1
- Urolithiasis (kidney stones): Conditionally recommend starting ULT 1
Strong Indications (Even Without Symptoms)
- Subcutaneous tophi present: Strongly recommend initiating ULT 1
- Radiographic damage attributable to gout on any imaging modality: Strongly recommend initiating ULT 1
- Frequent gout flares (≥2 per year): Strongly recommend initiating ULT 1
Conditional Indication
- Infrequent flares (<2 per year) but with >1 prior flare: Conditionally recommend initiating ULT 1
Special Considerations for Young Patients and Comorbidities
The 2017 EULAR guidelines recommend initiating ULT close to the time of first diagnosis in patients with: 1
- Age <40 years at presentation
- Very high serum uric acid >8.0 mg/dL (480 μmol/L)
- Comorbidities including renal impairment, hypertension, ischemic heart disease, or heart failure
Treatment Target Once Started
When ULT is initiated, target serum uric acid <6 mg/dL (360 μmol/L) for maintenance. 1 For severe gout with tophi, chronic arthropathy, or frequent attacks, target <5 mg/dL (300 μmol/L) until complete crystal dissolution occurs. 1
First-Line Medication Choice
Allopurinol is the first-line agent, started at low dose (100 mg/day, lower in CKD) and titrated upward every 2-4 weeks to reach target serum uric acid. 1 If allopurinol fails to achieve target or is not tolerated, switch to febuxostat or add/switch to a uricosuric agent. 1
Common Pitfall to Avoid
Do not treat asymptomatic hyperuricemia to prevent CKD progression. The 2025 KDOQI guidelines explicitly recommend against using uric acid-lowering agents in patients with CKD and asymptomatic hyperuricemia solely to delay CKD progression. 1 Treatment should only be initiated for symptomatic gout or the specific high-risk features outlined above.